Archon Biosciences
Archon Biosciences develops geometrically tunable protein therapeutics called Antibody Cages (AbCs), which integrate antibody affinity and specificity with generative protein design to target pathways inaccessible to other technologies. Its platform uses AI-driven structural engineering to create biologics with precise control over distribution, engagement, and function for improved treatment of disease. The organization aims to solve challenging drug discovery problems by advancing new classes of biologic medicines.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2023 Seattle business license
- Type
- Corporation Seattle business license
- Employees
- 26
- Registered name
- Archon Biosciences Inc Seattle business license
- Stage
- Seed
Is this your organization? Claim it
Fred Hutch-Led Synthesize Bio Raises $10M to Accelerate Drug Discovery Using AI Gene Expression Model
Seattle-based Synthesize Bio, led by Fred Hutchinson Cancer Center researchers, raised $10 million from Madrona to accelerate drug discovery using their AI model GEM-1, which predicts gene expression outcomes with lab-level accuracy. The startup aims to reduce drug development time and costs by simulating hypothetical lab experiments with generative genomics.
James Lazarovits - Co-Founder and CEO at Archon Biosciences
James Lazarovits is the CEO and Co-Founder of Archon Biosciences, a leader at the intersection of materials engineering and artificial intelligence. James brings over 15 years of experience building, mentoring, and investing in deep tech startups across AI, software, hardware, and robotics. Before founding Archon, James was at the forefront of AI-driven computational protein design as a post-doctoral fellow and later research faculty at the Institute for Protein Design at the University of Washington, under the direction of 2024 Nobel Laureate, David Baker. There, he contributed to pioneering methods that integrate machine learning and molecular engineering to create next-gen therapeutic…
University of Washington CoMotion Spinoffs Launch AI, Biotech, and Mobility Innovations in Early 2025
In the first half of 2025, multiple University of Washington spinoff companies supported by CoMotion licensed UW technology to enter markets with innovations in biotech, AI education tools, and smart parking solutions. These startups benefited from CoMotion’s development programs and grants to advance their technologies from lab research to commercial applications.
People
-
George Ueda Chief Technology Officer, Co-Founder
-
James Lazarovits Chief Executive Officer, Co-Founder
Online
Questions about Archon Biosciences
What is Archon Biosciences?
Archon Biosciences is a startup based in Seattle, Washington, US, that develops geometrically tunable protein therapeutics called Antibody Cages (AbCs). Its platform combines antibody affinity and specificity with AI-driven protein design to target pathways inaccessible to other technologies.
What has Archon Biosciences been in the news for?
A July 2025 story featured James Lazarovits as co-founder and CEO at Archon Biosciences.
Who are the people behind Archon Biosciences?
James Lazarovits is CEO and co-founder of Archon Biosciences. George Ueda is chief technology officer and co-founder.
Who invested in Archon Biosciences, and how much has it raised?
Members of Seattle Flow see Archon Biosciences' funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is Archon Biosciences based?
Archon Biosciences is based in Seattle, Washington, US.
When was Archon Biosciences founded?
Archon Biosciences was founded in 2023.